Based on its share price, down 75% in the last three years, it's easy to write off Moderna (NASDAQ: MRNA) as a biotech ...

As of market close on Friday, Jan. 24, Moderna stock is up 21.6% this week. Here's why.

Sneezing, fever, chills, vomiting, coughing — it’s not just one virus wreaking havoc this winter; it’s a combination of four ...

"We remain focused on our three strategic priorities: driving sales growth, delivering up to 10 product approvals over the ...

The article " After a Reset Year, Is Moderna Stock Poised for a Comeback? " first appeared on MarketBeat.

Moderna’s mRESVIA is the first FDA-approved mRNA therapy designed to prevent respiratory syncytial virus (RSV) in adults 60 and over. The EU, Norway, Iceland, and Qatar have also approved it.

No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...

Moderna CEO Stephane Bancel commented, "In 2024, we achieved $3.0 - 3.1 billion in product sales, approval of our RSV vaccine and continued to adapt our COVID-19 business for the endemic setting.

Alone and in combination with other lower respiratory tract disease signs and symptoms, dyspnea is the best predictor of severe RSV outcomes.